DE602004014189D1 - Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion - Google Patents

Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion

Info

Publication number
DE602004014189D1
DE602004014189D1 DE602004014189T DE602004014189T DE602004014189D1 DE 602004014189 D1 DE602004014189 D1 DE 602004014189D1 DE 602004014189 T DE602004014189 T DE 602004014189T DE 602004014189 T DE602004014189 T DE 602004014189T DE 602004014189 D1 DE602004014189 D1 DE 602004014189D1
Authority
DE
Germany
Prior art keywords
compound
methods
compositions
hcv
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004014189T
Other languages
German (de)
English (en)
Inventor
Elzbieta J Holsztynska
Ray Lo
Thomas W Sun
Steven X Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of DE602004014189D1 publication Critical patent/DE602004014189D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004014189T 2003-12-19 2004-12-18 Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion Expired - Fee Related DE602004014189D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53154303P 2003-12-19 2003-12-19
PCT/US2004/042717 WO2005063225A1 (en) 2003-12-19 2004-12-18 Compositions and methods for treating hepatitis c virus (hcv) infection

Publications (1)

Publication Number Publication Date
DE602004014189D1 true DE602004014189D1 (de) 2008-07-10

Family

ID=34738664

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014189T Expired - Fee Related DE602004014189D1 (de) 2003-12-19 2004-12-18 Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion

Country Status (7)

Country Link
US (1) US20050249805A1 (cg-RX-API-DMAC10.html)
EP (1) EP1699446B1 (cg-RX-API-DMAC10.html)
JP (1) JP2007514763A (cg-RX-API-DMAC10.html)
AT (1) ATE396718T1 (cg-RX-API-DMAC10.html)
DE (1) DE602004014189D1 (cg-RX-API-DMAC10.html)
ES (1) ES2308302T3 (cg-RX-API-DMAC10.html)
WO (1) WO2005063225A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7971730B2 (en) 2005-08-10 2011-07-05 The Regents Of The University Of California Collection tubes apparatus, systems and methods
WO2009029321A2 (en) * 2007-06-08 2009-03-05 Musc Foundation For Research Development Carboxylesterase-1 polymorphisms and methods of use therefor
US20090017108A1 (en) * 2007-07-11 2009-01-15 Alexander Yuzhakov Liposome compositions for treatment of hepatitis C
US10966431B2 (en) * 2007-09-11 2021-04-06 Freedom Towel Holdings, LLC. Refreshment towel and applied solution
US8182826B2 (en) * 2007-09-11 2012-05-22 Whitmire A Jeffrey Refreshment towel and applied solution
US9669405B2 (en) 2012-10-22 2017-06-06 The Regents Of The University Of California Sterilizable photopolymer serum separator
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
CN110220757B (zh) * 2019-06-05 2021-08-24 浙江龙传生物医药科技有限公司 用于药物代谢检测的血液保存剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971618A (en) * 1971-04-16 1990-11-20 Ici Americas Inc. Herbicide compositions
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
HRP20050168A2 (en) * 2002-08-23 2005-10-31 Rigel Pharmaceuticals Pyridyl substituted heterocycles useful for treating or preventing hcv infection

Also Published As

Publication number Publication date
EP1699446A1 (en) 2006-09-13
ATE396718T1 (de) 2008-06-15
EP1699446B1 (en) 2008-05-28
ES2308302T3 (es) 2008-12-01
WO2005063225A1 (en) 2005-07-14
US20050249805A1 (en) 2005-11-10
JP2007514763A (ja) 2007-06-07
WO2005063225A8 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
BRPI0415373A (pt) ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv
DK2250163T3 (da) Hepatitis C-virusinhibitorer
HRP20030139B1 (hr) Peptidomimetiäśki inhibitori proteaza
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
TW200612898A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MX2010002296A (es) Inhibidores iv de polimerasa de fosfadiazina hcv.
TW200621233A (en) HCV NS3-NS4A protease inhibition
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
IL196815A0 (en) Hepatitis c virus inhibitors
ATE250080T1 (de) Hcv ns3 proteaseinhibitoren
ATE396718T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
MY141506A (en) Virus therapeutic drug
TNSN06103A1 (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
NZ600527A (en) Antiviral compounds
ATE499942T1 (de) 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol
UA84579C2 (ru) Макроциклические карбоновые кислоты и ацилсульфонамиды как ингибиторы репликации вируса гепатита с

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee